Literature DB >> 34204094

Deciphering the Long Non-Coding RNAs and MicroRNAs Coregulation Networks in Ovarian Cancer Development: An Overview.

César López-Camarillo1,2, Erika Ruíz-García2,3, Yarely M Salinas-Vera4, Macrina B Silva-Cázares5, Olga N Hernández-de la Cruz1, Laurence A Marchat6, Dolores Gallardo-Rincón2,3.   

Abstract

Non-coding RNAs are emergent elements from the genome, which do not encode for proteins but have relevant cellular functions impacting almost all the physiological processes occurring in eukaryotic cells. In particular, microRNAs and long non-coding RNAs (lncRNAs) are a new class of small RNAs transcribed from the genome, which modulate the expression of specific genes at transcriptional and posttranscriptional levels, thus adding a new regulatory layer in the flux of genetic information. In cancer cells, the miRNAs and lncRNAs interactions with its target genes and functional pathways are deregulated as a consequence of epigenetic and genetic alterations occurring during tumorigenesis. In this review, we summarize the actual knowledge on the interplay of lncRNAs with its cognate miRNAs and mRNAs pairs, which interact in coregulatory networks with a particular emphasis on the mechanisms underlying its oncogenic behavior in ovarian cancer. Specifically, we reviewed here the evidences unraveling the relevant roles of lncRNAs/miRNAs pairs in altered regulation of cell migration, angiogenesis, therapy resistance, and Warburg effect. Finally, we also discussed its potential clinical implications in ovarian cancer and related endocrine disease therapies.

Entities:  

Keywords:  co-regulation networks; gene expression; long non-coding RNAs; microRNAs; ovarian cancer

Year:  2021        PMID: 34204094     DOI: 10.3390/cells10061407

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  2 in total

Review 1.  The Role of Long Non-Coding RNAs (lncRNAs) in Female Oriented Cancers.

Authors:  Faiza Naz; Imran Tariq; Sajid Ali; Ahmed Somaida; Eduard Preis; Udo Bakowsky
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

2.  The Enticing Path of miR Therapeutics: Difficult but Not without Prospects.

Authors:  Ajit Vikram
Journal:  Cells       Date:  2022-01-26       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.